Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ricolinostat with Gemcitabine and Cisplatin in Cholangiocarcinoma
NCT02856568Phase 1Withdrawn
- Sponsor
- Mayo Clinic
- Start
- May 2017
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ricolinostat in cholangiocarcinoma (CCA), sponsored by Mayo Clinic. Primary endpoint: Maximum Tolerated Dose. Planned start May 2017; status: withdrawn.
02
Drugs
ricolinostat
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02856568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02856568.